Neostigmine
Neostigmine has been studied in 4 papers since 2020: 2 trials and 1 observational study in people, 1 review; 2 in the past year. The newest paper, May 20, 2026: “Ten-year management of acute colonic pseudo-obstruction in a single UK center: a retrospective cohort study”.
See all 8 papers on neostigmine
At a glance
Independent labs found the same change in people. 3 independent labs in 2 countries; 5 trials, none about aging.
“The incidence of early postoperative cognitive decline in 0.04 mg/kg and 0.02 mg/kg groups was 10 and 15.7%, respectively, which were significantly lower than those in the control group (P = 0.013).”
1 of its findings points the other way.
- 3 independent labs in 2 countries
- 1 finding against
- 5 trials, none about aging
- Funders: Dalian Medical University and 1 more
- Human trial2
- Humans1
Studies in people
2 studies gave neostigmine to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Lowers the risk of postoperative cognitive dysfunction-22% (95% CI, -37 to -7) | Randomized trial7 days | 118 people≥65 yearsOlder adults | Anesthesia and analgesia, Dec 15, 2023 |
down: Lowers the risk of early postoperative cognitive decline10% and 15.7% incidence versus control; P = 0.013 down: Decreases extubation timesignificantly shorter than control; P < 0.001 no change: Has no effect on peripheral inflammatory factors | Randomized trial | 132 peopleelderlyOlder adults; elderly patients after radical gastrointestinal cancer surgery | BMC geriatrics, Oct 6, 2020 |
What did studies of neostigmine find?
4Studies of neostigmine measured 4 outcomes, among them BDNF, oxidative stress and ROS signaling and peripheral inflammatory factors.
BDNF
upin humans1
1 study
BDNF
upin humans1
Neostigmine increases BDNF in humans (P = .013).
“SOD and BDNF levels were increased ( P = .036 and .013, respectively) in the neostigmine group compared to the control group on the first day after surgery.”
Human trialserum0.04 mg/kg
Anesthesia and analgesia
Oxidative stress and ROS signaling
downin humans1
1 study
Oxidative stress and ROS signaling
downin humans1
Neostigmine inhibits oxidative stress and ROS signaling in humans (P = .016).
“Postoperative plasma MDA levels were significantly lower ( P = .016)”
Human trialplasma0.04 mg/kg
Anesthesia and analgesia
Peripheral inflammatory factors
no changein humans1
1 study
Peripheral inflammatory factors
no changein humans1
Neostigmine showed no clear effect on peripheral inflammatory factors in humans (elderly patients after radical gastrointestinal cancer surgery).
“In elderly patients, 0.02-0.04 mg/kg neostigmine could significantly reduce the incidence of early postoperative cognitive decline without affecting peripheral inflammatory factors.”
Human trialelderly patients after radical gastrointestinal cancer surgeryperipheral blood0.02-0.04 mg/kg
BMC geriatrics
Extubation time
downin humans1
1 study
Extubation time
downin humans1
Neostigmine decreases extubation time in humans (elderly patients after radical gastrointestinal cancer surgery) (significantly shorter than control; P < 0.001).
“The extubating and PACU times in 0.04 mg/kg and 0.02 mg/kg groups were significantly shorter than those in the control group (P < 0.001).”
Human trialelderly patients after radical gastrointestinal cancer surgery0.02 or 0.04 mg/kg
BMC geriatrics
What is neostigmine linked with?
2Studies link neostigmine with 2 measures: postoperative cognitive dysfunction and early postoperative cognitive decline.
Postoperative cognitive dysfunction
downin humans2upin humans1OR 0.31–1.74
2 studies
Postoperative cognitive dysfunction
downin humans2upin humans1OR 0.31–1.74
Neostigmine lowers the risk of postoperative cognitive dysfunction in humans (-22% (95% CI, -37 to -7)).
“Patients receiving neostigmine had a significantly reduced incidence of POCD compared to patients who were treated with placebo on the first day after surgery (-22%, 95% confidence interval [CI], -37 to -7)”
Human trial0.04 mg/kgn = 118
Anesthesia and analgesia
Neostigmine lowers the risk of postoperative cognitive dysfunction in humans (postoperative general anesthesia with neuromuscular blockade) (OR 0.31, 95% CI 0.15-0.63).
“administration of a higher dose (≥0.04 mg/kg) was associated with reduced POCD incidence compared to a lower dose (<0.04 mg/kg) (OR 0.31, 95% CI 0.15-0.63, p = 0.001)”
Reviewpostoperative general anesthesia with neuromuscular blockade≥0.04 mg/kg vs <0.04 mg/kg
Diagnostics (Basel, Switzerland)
Neostigmine raises the risk of postoperative cognitive dysfunction in humans (postoperative general anesthesia with neuromuscular blockade) (OR 1.74, 95% CI 1.00-3.02).
“neostigmine was associated with a higher risk of POCD than sugammadex (OR 1.74, 95% CI 1.00-3.02, p = 0.05)”
Reviewpostoperative general anesthesia with neuromuscular blockaden = 795
Diagnostics (Basel, Switzerland)
Early postoperative cognitive decline
downin humans1
1 study
Early postoperative cognitive decline
downin humans1
Neostigmine lowers the risk of early postoperative cognitive decline in humans (elderly patients after radical gastrointestinal cancer surgery) (10% and 15.7% incidence versus control; P = 0.013).
“The incidence of early postoperative cognitive decline in 0.04 mg/kg and 0.02 mg/kg groups was 10 and 15.7%, respectively, which were significantly lower than those in the control group (P = 0.013).”
Human trialelderly patients after radical gastrointestinal cancer surgery0.02 or 0.04 mg/kg
BMC geriatrics
Trial sponsors
Company4 trialsPhase 4881 people